Skip to main content
Download PDF
Download ePub
  • Integrative article
  • Open access
  • Published:

Understanding the phases of vaccine hesitancy during the COVID-19 pandemic

Israel Journal of Health Policy Research volume 11, Article number: 16 (2022) Cite this article

Abstract

Vaccine hesitancy is an important feature of every vaccination and COVID-19 vaccination is not an exception. During the COVID-19 pandemic, vaccine hesitancy has exhibited different phases and has shown both temporal and spatial variation in these phases. This has likely arisen due to varied socio-behavioural characteristics of humans and their response towards COVID 19 pandemic and its vaccination strategies. This commentary highlights that there are multiple phases of vaccine hesitancy: Vaccine Eagerness, Vaccine Ignorance, Vaccine Resistance, Vaccine Confidence, Vaccine Complacency and Vaccine Apathy. Though the phases seem to be sequential, they may co-exist at the same time in different regions and at different times in the same region. This may be attributed to several factors influencing the phases of vaccine hesitancy. The complexities of the societal reactions need to be understood in full to be addressed better. There is a dire need of different strategies of communication to deal with the various nuances of all of the phases. To address of vaccine hesitancy, an understanding of the societal reactions leading to various phases of vaccine hesitancy is of utmost importance.

Background

The deluge of COVID patients has overwhelmed healthcare systems all over the world. The only hope to controlCOVID-19 during the pandemic was earnest research on developing and producing vaccines against COVID-19.

Whenever there is vaccine introduction, vaccine hesitancy also comes into play due to the complex interaction of vaccine related factors, vaccinees’ dynamics, and other external issues [1]. The phenomenon of vaccine hesitancy existed long before the current pandemic and has recently been considered as one of the top ten threats to health by the World Health Organization [2]. The 3 “Cs” that inadvertently or otherwise influence vaccine acceptance are complacency, convenience and confidence [3]. In due course of time, some experts have tried to develop a measuring tool for assessing vaccine hesitancy in terms of 5C psychological antecedents of vaccination: confidence, complacency, convenience (constraints), calculation, and collective responsibility [4]. Stimulating the acceptance of vaccines against COVID-19 requires the comprehensive understanding of the reasons of willingness and related concerns of people and the trustworthy sources of information in their decision-making.

In relation to the COVID-19 pandemic, the world has also faced the unprecedented public health crisis of an infodemic, too much information including false information; and this has negatively impacted good decisions pertaining to health [5]. The spread of misinformation was not limited to disease transmission, but also accompanied the COVID vaccine roll out [6].

Main text

Different phases of vaccine hesitancy

Since the emergence of COVID 19 pandemic, there have been numerous studies on vaccine hesitancy related to COVID 19 vaccine [7,8,9,10,11,12,13,14,15]. Understanding of vaccine hesitancy has been different by experts in different parts of world. This has led to a diverse array of definitions [16, 17]. There is a need to understand this phenomenon as a behavioural characteristic which changes according to human mental capacity and thoughtfulness. Considering this, the very existence of vaccine hesitancy in an individual, family, community and global is dynamic and very complex.

It has been observed that the nature of vaccine hesitancy changes over time in the same population; and it changes as people experience subsequent vaccination [18]. In this paper, we describe various phases of vaccine hesitancy (Fig. 1) and how vaccine hesitancy has changed during the COVID 19 pandemic.

Fig. 1
figure 1

Various phases of Vaccine hesitancy during COVID 19 pandemic. There are multiple phases of vaccine hesitancy: Vaccine Eagerness, Vaccine Ignorance, Vaccine Resistance, Vaccine Confidence, Vaccine Complacency and Vaccine Apathy. These are societal reactions observed or expected to be observed during various periods of COVID 19 pandemic in different regions of world

Full size image

Vaccine eagerness/desperation

During the early stages of COVID pandemic, when there was great fear of mortality and morbidity due to SARS COV-2 virus amongst the general population, significant keenness towards vaccines amongst the public was observed [19, 20]. Most people all over the world were eagerly waiting for COVID 19 vaccine in order to get rid of the strict lockdowns and resume their normal life [21]. At that stage, the public was aware that even after the introduction of vaccine, they might have to wait to get vaccine access based on the prioritization criteria. This was because of limited vaccine availability in the initial phase and it took some time before it was made available widely. The waiting period for some sections of people in the society made them more desperate for vaccines. This was also seen amongst the parents who were more concerned about their children when there was no COVID 19 vaccines approved for children. During this phase of eagerness, a vast number of vaccine trials all over the world were conducted to test the efficacy and safety of the various vaccine candidates [22]. This societal reaction may not be considered as part of vaccine hesitancy by some experts but was an important phase encountered during this pandemic.

Vaccine ignorance

Ignorance may seem like bliss; but sometimes ignorance can be deadly. The United States has a process for Emergency Use Authorization (EUA) of new drugs and biologics. It is faster than full licensure but considered temporary [23]. The US Food and Drug Administration has issued EUAs for COVID-19 vaccines, but ignorance about the EUA of COVID 19 vaccines and the effectiveness of vaccine has led to some untoward results regarding acceptance of these vaccines all over the world. After the EUA of COVID-19 vaccines, people out of their ignorance started questioning the vaccine development, its efficacy, safety, and appropriateness for roll out in the general population [9, 24]. And moreover, none of the experts or researchers were aware of the effectiveness of the vaccine candidates against the then prevalent strains and subsequent mutant strains in future [22]. Some health experts also raised their eyebrows over the vaccine roll out after the EUA which prevented a major chunk of population from getting vaccinated. Either they were unaware of EUA and its procedural mechanism or they may not have been convinced with the EUA for COVID vaccines, as it was never done before. With the ignorance and confusion over COVID 19 vaccines roll out, people perceived themselves as guinea pigs for the COVID 19 vaccine drive by the government agencies [25]. The ignorance phase was inevitable since even some health care providers were not fully confident about the vaccine’s safety and efficacy.

Another aspect of hesitancy due to ignorance followed the lowering of preventive measures by vaccinated and even unvaccinated people under the misconception that the vaccine was the complete solution to COVID-19. People also were unaware of the fact that after partial or even a full course of vaccination, they may contract infection but the severity would be less. This was the phase when the concept of break-through infections was not common. These factors led to a rising incidence in infections due to increased transmission of COVID 19 virus in the community. This ignorance also fuelled vaccine hesitancy in the communities and gave antivaxxers material to propagate their agenda [26].

Vaccine resistance

Intertwining with the phase of vaccine ignorance, the phase of vaccine resistance also showed its presence during the COVID 19 pandemic. Amidst bizarre theories of staunch anti-vaxxers, reduction in number of severe cases and reporting of Adverse Events Following Immunization (AEFI) led to this phase of vaccine hesitancy. Though most of the AEFI were mild, a few rare ones were serious or severe. Arzarpaneh and colleagues associated 15 types of cognitive bias as possible contributors to vaccine hesitancy [9].

In this phase, social media was rife with posts disparaging the vaccines [27]. The theories of antivaccine supporters spreading the infodemic online through various social media platforms resulted in vaccine resistance in various communities [9, 28]. The anti-vaccine movement swept through privileged as well as under privileged communities all over the world. The rise of anti-vaccine movements may correspond with different characteristics of members of the population such as unawareness, anxiety and religious beliefs [26].

Vaccine confidence

This phase occurs when the morbidity and mortality due to an infection such as COVID-19 is primarily seen in unvaccinated individuals. It suggests to people that the vaccine is effective against the disease particularly in reducing hospitalizations and deaths [29]. In this phase, those who were hesitant initially due to their concern regarding vaccine novelty, composition and the processes of manufacture and delivery become vaccinated either for professional or personal reasons. As per protection motivation theory (PMT) and the health belief model, protective health behaviours, such as COVID-19 vaccination, will be adopted in due course of time if the individual rationally assesses threat to be severe with a high probability of occurrence [28, 30], and the individual perceives the overall benefits to exceed the risks and costs. Most countries have undergone severe waves of the pandemic and in most countries COVID 19 vaccines are either free or affordable to most sections of society. The combination of these conditions increased confidence in getting the vaccine during this phase.

Vaccine complacency

Vaccine complacency is a recurring impediment to vaccination [31]. With respect to COVID 19 vaccination coverage, this occurs during the period when there is a low rate of transmission and illness between the waves of the pandemic. During this phase, although people may have taken no dose or just a first dose of the vaccine, complacency prevents them from getting fully vaccinated. This continues to make the public as a whole vulnerable to COVID 19 due to inadequate population immunity against the virus and it also increases the risk of development of new mutant strains.

There have been instances of vaccine complacency in the past against other vaccination drives [8]. Vaccine complacency for the same vaccine differs from region to region at the same or different periods of time depending on socio-behavioural factors. This temporo-spatial variation of vaccine complacency occurs with COVID 19 too. During COVID-19, there has also been a much lower occurrence of influenza across the world. Although higher influenza immunization rates were seen in some places [31], use of masks and social distancing probably also played a major role in this phenomenon. Experts fear that this may lead to complacency towards periodic influenza vaccination in the coming seasons [32, 33]. However, while the benefits of COVID 19 vaccination are distinct and well acknowledged by international agencies, vaccine complacency continues to reduce the prospective assistances of vaccination at population level in combating this pandemic. This may also arise when milder strains are in circulation and people become complacent to vaccination.

Vaccine apathy

Although only a few experts describe vaccine apathy as different from vaccine hesitancy [34], we consider vaccine apathy as a component of vaccine hesitancy. Vaccine apathy is defined as disinterest or feeling of not being interested in vaccination. It is characterized by weak attitudes towards getting vaccinated and associated with little time spent considering vaccination [35]. This may occur distinctly, or it may co-exist with complacency or other phases of vaccine hesitancy in the community.

Vaccine apathy occurs across various socioeconomic groups. For some, vaccination may be low-priority due to loosening of COVID-19 restrictions and return of life back to normal; whereas some individuals may be overwhelmed with higher priority problems of daily earning and other social responsibilities. Determining the magnitude of the vaccine-apathetic population is challenging. It is difficult to predict, like voters’ turnout in polls. Another problem in determining the true magnitude of the vaccine-apathetic population is that people tend to want to present themselves in a manner they think is favourable, so-called social desirability bias [36]. Hence apathetic people may describe their disinterest in personal terms, e.g. lack of concern, indifference to preventive health care, health disinterest/fatalism, rather than in terms related directly to vaccine efficacy and safety, and issues with the clinical trials.

Persons with antivaccine positions differ from apathetic people. The former have strongly held and highly defended attitudes, whereas in comparison the latter have weakly negative attitudes toward vaccines. Therefore, effective communication strategies to influence these two groups differ markedly. In the apathy phase of vaccine hesitancy, vaccine promotion approaches specifically addressing the apathetic population may be a vital component in increasing the vaccination coverage and for achieving the national vaccination goals.

Conclusions

Though the phases of vaccine hesitancy have been described in sequential manner in this article, various phases can co-exist at the same time in different regions or even in the same region. Several factors leading to various societal reactions can influence the phases of vaccine hesitancy with respect to stage of the pandemic and geographical location. Various solutions to the problem of vaccine hesitancy have been proposed, but the comprehension of its complexity and the origin, existence and spread of each of its types or phases is essential to address it more convincingly [36,37,38]. Humanity is in dire need of a solution for vaccine hesitancy, and we believe that the solution lies ineffective communication and appropriate mass education. The communication strategies for each phase need to be planned and implemented meticulously. We may learn from the experiences of Israel’s successful COVID vaccination program in addressing vaccine hesitancy and achieving a very high coverage rate during the first three months of the initiation of COVID 19 vaccination [38]. There are many countries which have handled vaccine hesitancy and rolled out the vaccination program successfully with effective communication. Learning from different parts of world in dealing various phases of vaccine hesitancy may help each country make effective communication plans for individuals, families, communities, and the nation as a whole.

The societal reaction to the vaccine inequity in regards to vaccine availability in different parts of world may also lead to vaccine hesitancy which has not been discussed here and is a limitation of this paper. In addition, COVID-19 vaccination has been primarily an issue of adult immunization. In low and middle income countries, adult immunization is in its infancy [39]. Therefore, successful approaches for addressing vaccine hesitancy that are developed and implemented during the COVID-19 pandemic might be helpful in shaping the future direction of adult vaccination in the world.

Availability of data and materials

Not applicable.

Abbreviations

AEFI:

Adverse Event Following Immunization

EUA:

Emergency Use Authorization

PMT:

Protection motivation theory

References

  1. Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy: understanding better to address better. Isr J Health Policy Res. 2016;1(5):2. https://doi.org/10.1186/s13584-016-0062-y.

    Article  Google Scholar 

  2. Lahariya C, Kumar D. Frequently asked questions on vaccine hesitancy. In: Vashistha VM, Kalra A, editors. FAQs on vaccines and immunization practices. 3rd ed. New Delhi: Jaypee Brothers Medical Publishers Pvt Ltd; 2021. p. 167–73.

    Google Scholar 

  3. MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4. https://doi.org/10.1016/j.vaccine.2015.04.036.

    Article  PubMed  Google Scholar 

  4. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Bohm R. Beyond confidence: development of a measure assessing the 5C psychological antecedents of vaccination. PLoS ONE. 2018;13(12):e0208601. https://doi.org/10.1371/journal.pone.0208601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cinelli M, Quattrociocchi W, Galeazzi A, Valensise CM, Brugnoli E, Schmidt AL, et al. The COVID-19 social media infodemic. Sci Rep. 2020;10(1):16598. https://doi.org/10.1038/s41598-020-73510-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bar-Lev S, Reichman S, Barnett-Itzhaki Z. Prediction of vaccine hesitancy based on social media traffic among Israeli parents using machine learning strategies. Isr J Health Policy Res. 2021;10(1):49. https://doi.org/10.1186/s13584-021-00486-6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775–9. https://doi.org/10.1007/s10654-020-00671-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Reid JA, Mabhala MA. Ethnic and minority group differences in engagement with COVID-19 vaccination programmes - at Pandemic Pace; when vaccine confidence in mass rollout meets local vaccine hesitancy. Isr J Health Policy Res. 2021;10(1):33. https://doi.org/10.1186/s13584-021-00467-9 (Erratum in: Isr J Health Policy Res. 2021;10(1):60).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Azarpanah H, Farhadloo M, Vahidov R, Pilote L. Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases. BMC Public Health. 2021;21(1):1686. https://doi.org/10.1186/s12889-021-11745-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Aw J, Seng JJB, Seah SSY, Low LL. COVID-19 vaccine hesitancy-a scoping review of literature in high-income countries. Vaccines (Basel). 2021;9(8):900. https://doi.org/10.3390/vaccines9080900.

    Article  CAS  Google Scholar 

  11. Chandani S, Jani D, Sahu PK, Kataria U, Suryawanshi S, Khubchandani J, et al. COVID-19 vaccination hesitancy in India: state of the nation and priorities for research. Brain Behav Immun Health. 2021;18:100375. https://doi.org/10.1016/j.bbih.2021.100375.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245–51. https://doi.org/10.1016/j.puhe.2021.02.025.

    Article  CAS  PubMed  Google Scholar 

  13. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 vaccination hesitancy in the United States: a rapid national assessment. J Community Health. 2021;46(2):270–7.

    Article  PubMed  Google Scholar 

  14. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. Hum Vaccin Immunother. 2020;16(11):2586–93. https://doi.org/10.1080/21645515.2020.1780846.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wang Q, Yang L, Jin H, Lin L. Vaccination against COVID-19: a systematic review and meta-analysis of acceptability and its predictors. Prev Med. 2021;150:106694. https://doi.org/10.1016/j.ypmed.2021.106694.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lahariya C. Vaccine epidemiology: a review. J Fam Med Prim Care. 2016;5:7–15. https://doi.org/10.4103/2249-4863.184616.

    Article  Google Scholar 

  17. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med. 2021;27(8):1338–9. https://doi.org/10.1038/s41591-021-01459-7.

    Article  CAS  PubMed  Google Scholar 

  18. Siegler AJ, Luisi N, Hall EW, Bradley H, Sanchez T, Lopman BA, et al. Trajectory of COVID-19 vaccine hesitancy over time and association of initial vaccine hesitancy with subsequent vaccination. JAMA Netw Open. 2021;4(9):e2126882. https://doi.org/10.1001/jamanetworkopen.2021.26882.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Quadros S, Garg S, Ranjan R, Vijayasarathi G, Mamun MA. Fear of COVID 19 infection across different cohorts: a scoping review. Front Psychiatry. 2021;12:708430. https://doi.org/10.3389/fpsyt.2021.708430.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA. 2020;323(24):2458–9. https://doi.org/10.1001/jama.2020.8711.

    Article  CAS  PubMed  Google Scholar 

  21. Zachreson C, Chang SL, Cliff OM, Prokopenko M. How will mass-vaccination change COVID-19 lockdown requirements in Australia? Lancet Reg Health West Pac. 2021;14:100224. https://doi.org/10.1016/j.lanwpc.2021.100224.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Avorn J, Kesselheim A. Regulatory decision-making on COVID-19 vaccines during a public health emergency. JAMA. 2020;324(13):1284–5. https://doi.org/10.1001/jama.2020.17101.

    Article  CAS  PubMed  Google Scholar 

  23. USFDA. Emergency use authorization for vaccines explained. https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained. Accessed 09 Jan 2022 (2020).

  24. Kollątaj BM, Kollątaj WP, Karwat ID, Sobieszczanski J, Panasiuk L. Anti-vaccine movements-health care, ignorance or a diversion aimed at destabilizing the health situation? Part 2. Contemporary conditions for the functioning and development of anti-vaccination movements. Ann Agric Environ Med. 2020;27(4):553–61. https://doi.org/10.26444/aaem/126014.

    Article  PubMed  Google Scholar 

  25. Islam MS, Kamal AM, Kabir A, Southern DL, Khan SH, Hasan SMM, Sarkar T, Sharmin S, Das S, Roy T, Harun MGD, Chughtai AA, Homaira N, Seale H. COVID-19 vaccine rumors and conspiracy theories: the need for cognitive inoculation against misinformation to improve vaccine adherence. PLoS ONE. 2021;16(5):e0251605. https://doi.org/10.1371/journal.pone.0251605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Edwards B, Biddle N, Gray M, Sollis K. COVID-19 vaccine hesitancy and resistance: correlates in a nationally representative longitudinal survey of the Australian population. PLoS ONE. 2021;16(3):e0248892. https://doi.org/10.1371/journal.pone.0248892.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Burki T. The online anti-vaccine movement in the age of COVID-19. Lancet Digit Health. 2020;2(10):e504–5. https://doi.org/10.1016/S2589-7500(20)30227-2.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gerend MA, Shepherd JE. Predicting human papillomavirus vaccine uptake in young adult women: comparing the health belief model and theory of planned behavior. Ann Behav Med. 2012;44(2):171–80. https://doi.org/10.1007/s12160-012-9366-5 (Erratum in: Ann Behav Med. 2012;44(2):293).

    Article  PubMed  Google Scholar 

  29. Macchia A, Ferrante D, Angeleri P, Biscayart C, Mariani J, Esteban S, et al. Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Netw Open. 2021;4(10):e2130800. https://doi.org/10.1001/jamanetworkopen.2021.30800.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Rogers RW. A protection motivation theory of fear appeals and attitude change1. J Psychol. 1975;91(1):93–114. https://doi.org/10.1080/00223980.1975.9915803.

    Article  PubMed  Google Scholar 

  31. Palache A, Rockman S, Taylor B, Akcay M, Billington JK, Barbosa P. IFPMA Influenza Vaccine Supply (IFPMA IVS) task force. Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use. Vaccine. 2021;39(41):6081–7. https://doi.org/10.1016/j.vaccine.2021.08.097.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gonzalez-Block MA, Gutierrez-Calderon E, Pelcastre-Villafuerte BE, Arroyo-Laguna J, Comes Y, Crocco P, et al. Influenza vaccination hesitancy in five countries of South America. Confidence, complacency and convenience as determinants of immunization rates. PLoS ONE. 2020;15(12):e0243833. https://doi.org/10.1371/journal.pone.0243833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gonzalez-Block MA, Pelcastre-Villafuerte BE, Riva Knauth D, Fachel-Leal A, Comes Y, Crocco P, et al. Influenza vaccination hesitancy in large urban centers in South America. Qualitative analysis of confidence, complacency and convenience across risk groups. PLoS ONE. 2021;16(8):e0256040. https://doi.org/10.1371/journal.pone.0256040.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wood S, Schulman K. When vaccine apathy, not hesitancy, drives vaccine disinterest. JAMA. 2021;325(24):2435–6. https://doi.org/10.1001/jama.2021.7707.

    Article  CAS  PubMed  Google Scholar 

  35. Latkin CA, Edwards C, Davey-Rothwell MA, Tobin KE. The relationship between social desirability bias and self-reports of health, substance use, and social network factors among urban substance users in Baltimore, Maryland. Addict Behav. 2017;73:133–6. https://doi.org/10.1016/j.addbeh.2017.05.005.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kumar D, Mathur M, Tanu T, Singh M, Kumari N, Mathur M, et al. Setting up an epidemiological surveillance system for vaccine hesitancy outbreaks and illustration of its steps of investigation. Fam Med Community Health. 2021;9(3):e001080. https://doi.org/10.1136/fmch-2021-001080.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Rosen B, Waitzberg R, Israeli A. Israel’s rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res. 2021;10:6.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Rosen B, Waitzberg R, Israeli A, Hartal M, Davidovitch N. Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel’s COVID-19 vaccination program. Isr J Health Policy Res. 2021;10(1):43. https://doi.org/10.1186/s13584-021-00481-x.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lahariya C, Bhardwaj P. Adult vaccination in India: status and the way forward. Hum Vaccin Immunother. 2020;16(7):1508–10. https://doi.org/10.1080/21645515.2019.1692564.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of PSM, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, 834001, India

    Dewesh Kumar & Tanya Tanu

  2. Immunization Technical Support Unit, Ministry of Health and Family Welfare, New Delhi, India

    Mansi Mathur

  3. Department of Community Medicine, Subharti Medical College, Meerut, U.P., India

    Nitesh Kumar

  4. Department of PSM, SNMMC, Dhanbad, Jharkhand, India

    Rishabh Kumar Rana

  5. Department of Community Medicine, Index Medical College, Indore, M.P., India

    Rahul Chandra Tiwary

  6. Department of Community and Family Medicine, AIIMS, Jodhpur, Rajasthan, India

    Pankaja Ravi Raghav

  7. Subregional Team Leader Office, WHO Country Office for India, Ranchi, Jharkhand, India

    Amarendra Kumar

  8. Orbi Health, New Delhi, Delhi, India

    Neelesh Kapoor

  9. Department of Community Medicine, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India

    Medha Mathur

  10. Department of Community Medicine, Government Medical College, Khandwa, M.P., India

    Soumitra Sethia

  11. Foundation for People-Centric-Health Systems, New Delhi, India

    Chandrakant Lahariya

Authors
  1. Dewesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mansi Mathur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nitesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rishabh Kumar Rana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rahul Chandra Tiwary
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pankaja Ravi Raghav
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amarendra Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Neelesh Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Medha Mathur
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tanya Tanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Soumitra Sethia
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chandrakant Lahariya
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: DK, MaM, PRR, CL, RKR and NeK; Literature search: RCT, TT, SS, NiK, AK, MeM; Writing–original draft: DK, MaM, TT, SS, RKR; Writing–review and editing: all authors. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Dewesh Kumar.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent of publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, D., Mathur, M., Kumar, N. et al. Understanding the phases of vaccine hesitancy during the COVID-19 pandemic. Isr J Health Policy Res 11, 16 (2022). https://doi.org/10.1186/s13584-022-00527-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13584-022-00527-8

Keywords

Israel Journal of Health Policy Research

ISSN: 2045-4015